In this work we determined that the ICD induced by the CD47-agonist peptide, PKHB1, has a therapeutic potential, as the PKHB1-TCL was able to induce antitumor immune responses ex vivo and in vivo in an established L5178Y-R tumor. Here, CD47 is linked to neoplasm.